Rochester, NY 8/6/2009 7:47:23 PM
Pre-Market - Celgene Corporation CELG, Celgene two Company Sponsored Studies of Amrubicin in Relapsed Small Cell Lung Cancer
Celgene Corporation CELG
Last Wednesday Celgene posted the results from two company sponsored studies of Amrubicin in relapsed small cell lung cancer at the 13th World Conference on Lung Cancer in San Francisco, Calif.
http://StockEinstein.com offers free daily stock alerts on companies ready to run. Scroll to the bottom of this page to signup for free stock alerts and visit our site.
Amrubicin through an analysis of decreases in left-ventricular ejection fraction, or LVEF. LVEF is a measure of the fraction of blood pumped out of the left ventricle with each heart beat.
StockEinstein.com has a dedicated team uncovering stocks ready to break and run. We apply time tested criteria and when one of these stocks meets or exceeds our benchmarks, our subscribers are immediately notified directly to their in-box.
This is a free service available only to our subscribers. Scroll to the bottom of this page to signup for free stock alerts and visit our site.
During 2009 our alerts have resulted in an average price gain of 80%+.
Disclaimer: Full disclaimer at http://StockEinstein.com/disclaimer.php
IMPORTANT: Never invest in any stock featured in any press release, email or website unless you can afford the loss of your entire investment. Stocks and particularly penny stocks have the possibility for dramatic gains, and also losses. Neither StockEinstein, nor any of its affiliates are registered investment advisors or broker dealers.
